The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Southern California (USC) a $472,863 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on targeting the herpes simplex virus type 1 (HSV-1) UL37 deamidase enzyme. The project aims to identify and characterize inhibitors of the UL37 deamidase, which can suppress the virus's ability to evade host innate immune defenses. This pilot study will provide proof-of-concept for a new antiviral approach and develop tools to further investigate the role of protein deamidation in fundamental biological processes. The grant period runs from May 2024 to March 2026.
Generated 1/28/25, 8:47 AM